Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.

Crittenden NE, Buchanan LA, Pinkston CM, Cave B, Barve A, Marsano L, McClain CJ, Jones CM, Marvin MR, Davis EG, Kuns-Adkins CB, Gedaly R, Brock G, Shah MB, Rosenau J, Cave MC.

Liver Transpl. 2016 May;22(5):635-43. doi: 10.1002/lt.24422.

2.

Climate confusion among U.S. teachers.

Plutzer E, McCaffrey M, Hannah AL, Rosenau J, Berbeco M, Reid AH.

Science. 2016 Feb 12;351(6274):664-5. doi: 10.1126/science.aab3907. No abstract available.

PMID:
26912845
3.

Hepatitis C virus infection in heart transplantation: is ventricular assist device therapy an option?

Rajagopalan N, Hoopes CW, Rosenau J.

Transplantation. 2013 Aug 27;96(4):e23-4. doi: 10.1097/TP.0b013e31829c24a6. No abstract available.

PMID:
23958885
4.

Science denial: a guide for scientists.

Rosenau J.

Trends Microbiol. 2012 Dec;20(12):567-9. doi: 10.1016/j.tim.2012.10.002.

PMID:
23164600
5.

High rate of unperceived hearing loss in patients after liver transplantation.

Rifai K, Pischke S, Agne C, Rosenau J, Klempnauer JL, Manns MP.

Clin Transplant. 2012 Jul-Aug;26(4):577-80. doi: 10.1111/j.1399-0012.2011.01592.x. Epub 2012 Jan 26.

PMID:
22280451
6.

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation.

Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann HL, Rosenau J, Bock CT, Savas B, Helfritz F, Lehner F, Strassburg CP, Klempnauer J, Wursthorn K, Lehmann U, Manns MP, Herrmann E, Wedemeyer H.

J Hepatol. 2012 Jan;56(1):115-22. doi: 10.1016/j.jhep.2011.06.016. Epub 2011 Jul 14.

PMID:
21762665
7.

Dispatches from the evolution wars: shifting tactics and expanding battlefields.

Branch G, Scott EC, Rosenau J.

Annu Rev Genomics Hum Genet. 2010;11:317-38. doi: 10.1146/annurev-genom-082509-141815. Review.

PMID:
20504219
8.

Changes in plasma amino acids during extracorporeal liver support by fractionated plasma separation and adsorption.

Rifai K, Das A, Rosenau J, Ernst T, Kretschmer U, Haller H, Fliser D, Manns MP.

Artif Organs. 2010 Feb;34(2):166-70. doi: 10.1111/j.1525-1594.2009.00763.x. Epub 2009 Oct 10.

PMID:
19817727
9.

A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.

Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL.

Antivir Ther. 2008;13(4):547-54.

PMID:
18672533
10.

Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.

Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, Klempnauer J, Tillmann HL, Manns MP, Rosenau J.

Liver Transpl. 2008 Apr;14(4):435-42. doi: 10.1002/lt.21343.

11.

Longer survival of liver transplant recipients with hepatitis virus coinfections.

Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL.

Clin Transplant. 2007 Mar-Apr;21(2):258-64.

PMID:
17425755
12.

Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation.

Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP, Manns MP.

Liver Transpl. 2007 Mar;13(3):367-73.

13.

HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.

Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, Finger A, Michel G, Nashan B, Kuse ER, Klempnauer J, Tillmann HL, Manns MP.

J Hepatol. 2007 Apr;46(4):635-44. Epub 2007 Jan 25.

PMID:
17316869
14.

Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus).

Rifai K, Hafer C, Rosenau J, Athmann C, Haller H, Peter Manns M, Fliser D.

Scand J Gastroenterol. 2006 Oct;41(10):1212-7.

PMID:
16990208
15.

Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response.

Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, Nashan B, Klempnauer J, Strassburg CP, Wedemeyer H, Manns MP.

Transpl Int. 2006 Oct;19(10):828-33.

16.

A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation.

Rifai K, Kirchner GI, Bahr MJ, Cantz T, Rosenau J, Nashan B, Klempnauer JL, Manns MP, Strassburg CP.

Liver Transpl. 2006 Mar;12(3):411-5.

17.

Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation.

Bahr MJ, Beckermann JG, Rifai K, Gehrmann L, Rosenau J, Klempnauer J, Strassburg CP, Manns MP.

Transplant Proc. 2005 May;37(4):1703-4.

PMID:
15919437
18.

Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.

Tillmann HL, Bock CT, Bleck JS, Rosenau J, Böker KH, Barg-Hock H, Becker T, Trautwein C, Klempnauer J, Flemming P, Manns MP.

Liver Transpl. 2003 Feb;9(2):191-6.

19.

Discussion on the association between hepatitis C infection and survival after orthotopic liver transplantation.

Bahr MJ, Rosenau J, Manns MP.

Gastroenterology. 2002 Dec;123(6):2160; author reply 2160. No abstract available.

PMID:
12454885
20.

Immunosuppression and the prognosis of patients suffering from myeloproliferative disorders after liver transplantation.

Bahr MJ, Rosenau J, Tietge UJ, Caselitz M, Hofmann MW, Klempnauer J, Böker KH, Strassburg CP, Manns MP.

Transplant Proc. 2002 Aug;34(5):1493-4. No abstract available.

PMID:
12176453
21.

Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.

Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP, Boeker KH.

Transplantation. 2002 Feb 15;73(3):386-94.

PMID:
11884935
22.

Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation.

Rosenau J, Tillmann HL, Bahr MJ, Trautwein C, Boeker KH, Nashan B, Klempnauer J, Manns MP.

Transplant Proc. 2001 Nov-Dec;33(7-8):3637-8. No abstract available.

PMID:
11750544
23.

Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy.

Benten D, Widjaja A, von Depka M, Flemming P, Trautwein C, Böker K, Vogel A, Rosenau J, Manns MP.

Z Gastroenterol. 2001 Oct;39(10):837-40.

PMID:
11605152
24.

Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.

Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J.

Lancet. 2001 Feb 24;357(9256):587-91.

PMID:
11558484
26.

Successful orthotopic liver transplantation.

Tillmann HL, Rosenau J, Trautwein C, Boeker KH, Manns MP.

Gastroenterology. 2001 May;120(6):1561-2. No abstract available.

PMID:
11339236
27.

Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil.

Barkmann A, Nashan B, Schmidt HH, Böker KH, Emmanouilidis N, Rosenau J, Bahr MJ, Hoffmann MW, Manns MP, Klempnauer J, Schlitt HJ.

Transplantation. 2000 May 15;69(9):1886-90.

PMID:
10830227
28.

Diagnosis of mycobacterial infections by nucleic acid amplification: 18-month prospective study.

Kirschner P, Rosenau J, Springer B, Teschner K, Feldmann K, Böttger EC.

J Clin Microbiol. 1996 Feb;34(2):304-12.

29.

2-AMINO-5-ARYL-2-OXAZOLINES. POTENT NEW ANORECTIC AGENTS.

POOS GI, CARSON JR, ROSENAU JD, ROSZKOWSKI AP, KELLEY NM, MCGOWIN J.

J Med Chem. 1963 May;6:266-72. No abstract available.

PMID:
14185981
30.

BICYCLIC BASES.IV. ARYL SUBSTITUTED BRIDGED HYDROISOINDOLINES.

POOS GI, LEHMAN MM, LANDIS EB, ROSENAU JD.

J Med Pharm Chem. 1962 Sep;91:883-96. No abstract available.

PMID:
14056432

Supplemental Content

Loading ...
Support Center